This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 46/4/975    most recent 01.HYP.0000176237.74820.75v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imig, J. D. Articles by Hammock, B. D. Search for Related Content PubMed PubMed Citation Articles by Imig, J. D. Articles by Hammock, B. D. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Kidney Diseases Hazardous Substances DB SODIUM CHLORIDE Related Collections Cardio-renal physiology/pathophysiology Lipids Hypertension - basic studies

(Hypertension. 2005;46:975.)
© 2005 American Heart Association, Inc.

Part 2 Original Articles

An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension

John D. Imig; Xueying Zhao; Constantine Z. Zaharis; Jeffrey J. Olearczyk; David M. Pollock; John W. Newman; In-Hae Kim; Takaho Watanabe; Bruce D. Hammock

From the Vascular Biology Center (J.D.I., X.Z., C.Z.Z., J.J.O., D.M.P.), and the Departments of Physiology (J.D.I.), Pharmacology (X.Z.), and Surgery (D.M.P.), Medical College of Georgia, Augusta, and the Department of Entomology and Cancer Center (J.W.N., I.-H.K., T.W., B.D.H.), University of California at Davis.

Correspondence to John D. Imig, PhD, Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500. E-mail jdimig{at}mail.mcg.edu

The present study tested the hypothesis that increasing epoxyeicosatrienoic acids by inhibition of soluble epoxide hydrolase (sEH) would lower blood pressure and ameliorate renal damage in salt-sensitive hypertension. Rats were infused with angiotensin and fed a normal-salt diet or an 8% NaCl diet for 14 days. The sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), was given orally to angiotensin-infused animals during the 14-day period. Plasma AUDA metabolite levels were measured, and they averaged 10±2 ng/mL in normal-salt angiotensin hypertension and 19±3 ng/mL in high-salt angiotensin hypertension on day 14 in the animals administered the sEH inhibitor. Mean arterial blood pressure averaged 161±4 mm Hg in normal-salt and 172±5 mm Hg in the high-salt angiotensin hypertension groups on day 14. EH inhibitor treatment significantly lowered blood pressure to 140±5 mm Hg in the normal-salt angiotensin hypertension group and to 151±6 mm Hg in the high-salt angiotensin hypertension group on day 14. The lower arterial blood pressures in the AUDA-treated groups were associated with increased urinary epoxide-to-diol ratios. Urinary microalbumin levels were measured, and ED-1 staining was used to determine renal damage and macrophage infiltration in the groups. Two weeks of AUDA treatment decreased urinary microalbumin excretion in the normal-salt and high-salt angiotensin hypertension groups and macrophage number in the high-salt angiotensin hypertension group. These data demonstrate that sEH inhibition lowers blood pressure and ameliorates renal damage in angiotensin-dependent, salt-sensitive hypertension.

Key Words: kidney • inflammation • endothelium-derived factors • albuminuria

This article has been cited by other articles:

				M. Manhiani, J. E. Quigley, S. F. Knight, S. Tasoobshirazi, T. Moore, M. W. Brands, B. D. Hammock, and J. D. Imig Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension Am J Physiol Renal Physiol, September 1, 2009; 297(3): F740 - F748. [Abstract] [Full Text] [PDF]

				A. Luria, C. Morisseau, H.-J. Tsai, J. Yang, B. Inceoglu, B. De Taeye, S. M. Watkins, M. M. Wiest, J. B. German, and B. D. Hammock Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase Am J Physiol Endocrinol Metab, August 1, 2009; 297(2): E375 - E383. [Abstract] [Full Text] [PDF]

				J.-Y. Liu, S.-H. Park, C. Morisseau, S. H. Hwang, B. D. Hammock, and R. H. Weiss Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol. Cancer Ther., August 1, 2009; 8(8): 2193 - 2203. [Abstract] [Full Text] [PDF]

				D. Ai, W. Pang, N. Li, M. Xu, P. D. Jones, J. Yang, Y. Zhang, N. Chiamvimonvat, J. Y.-J. Shyy, B. D. Hammock, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy PNAS, January 13, 2009; 106(2): 564 - 569. [Abstract] [Full Text] [PDF]

				D. J. Behm, A. Ogbonna, C. Wu, C. L. Burns-Kurtis, and S. A. Douglas Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 231 - 239. [Abstract] [Full Text] [PDF]

				H. C. Hercule, W.-H. Schunck, V. Gross, J. Seringer, F. P. Leung, S. M. Weldon, A. Ch. da Costa Goncalves, Y. Huang, F. C. Luft, and M. Gollasch Interaction Between P450 Eicosanoids and Nitric Oxide in the Control of Arterial Tone in Mice Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 54 - 60. [Abstract] [Full Text] [PDF]

				A. E. EnayetAllah, A. Luria, B. Luo, H.-J. Tsai, P. Sura, B. D. Hammock, and D. F. Grant Opposite Regulation of Cholesterol Levels by the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase J. Biol. Chem., December 26, 2008; 283(52): 36592 - 36598. [Abstract] [Full Text] [PDF]

				K. L. Fife, Y. Liu, K. R. Schmelzer, H.-J. Tsai, I.-H. Kim, C. Morisseau, B. D. Hammock, and D. L. Kroetz Inhibition of Soluble Epoxide Hydrolase Does Not Protect against Endotoxin-Mediated Hepatic Inflammation J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 707 - 715. [Abstract] [Full Text] [PDF]

				G. Irusta, M.J. Murphy, W.D. Perez, and J.D. Hennebold Dynamic expression of epoxyeicosatrienoic acid synthesizing and metabolizing enzymes in the primate corpus luteum Mol. Hum. Reprod., August 1, 2007; 13(8): 541 - 548. [Abstract] [Full Text] [PDF]

				H. Huang, C. Morisseau, J. Wang, T. Yang, J. R. Falck, B. D. Hammock, and M.-H. Wang Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats Am J Physiol Renal Physiol, July 1, 2007; 293(1): F342 - F349. [Abstract] [Full Text] [PDF]

				A. A. Spector and A. W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012. [Abstract] [Full Text] [PDF]

				A. Luria, S. M. Weldon, A. K. Kabcenell, R. H. Ingraham, D. Matera, H. Jiang, R. Gill, C. Morisseau, J. W. Newman, and B. D. Hammock Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice J. Biol. Chem., February 2, 2007; 282(5): 2891 - 2898. [Abstract] [Full Text] [PDF]

				C. R. Lee, K. E. North, M. S. Bray, M. Fornage, J. M. Seubert, J. W. Newman, B. D. Hammock, D. J. Couper, G. Heiss, and D. C. Zeldin Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study Hum. Mol. Genet., May 15, 2006; 15(10): 1640 - 1649. [Abstract] [Full Text] [PDF]

				I. Fleming and R. Busse Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function Hypertension, April 1, 2006; 47(4): 629 - 633. [Abstract] [Full Text] [PDF]